HomeCompareANSLY vs ABBV

ANSLY vs ABBV: Dividend Comparison 2026

ANSLY yields 2.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.5K in total portfolio value
10 years
ANSLY
ANSLY
● Live price
2.76%
Share price
$76.76
Annual div
$2.12
5Y div CAGR
-5.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$184.28
Full ANSLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ANSLY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANSLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANSLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANSLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANSLY
Annual income on $10K today (after 15% tax)
$234.62/yr
After 10yr DRIP, annual income (after tax)
$156.64/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,899.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANSLY + ABBV for your $10,000?

ANSLY: 50%ABBV: 50%
100% ABBV50/50100% ANSLY
Portfolio after 10yr
$62.6K
Annual income
$12,478.02/yr
Blended yield
19.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ANSLY
No analyst data
Altman Z
3.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANSLY buys
0
ABBV buys
0
No recent congressional trades found for ANSLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANSLYABBV
Forward yield2.76%3.06%
Annual dividend / share$2.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-5.3%40.6%
Portfolio after 10y$22.8K$102.3K
Annual income after 10y$184.28$24,771.77
Total dividends collected$2.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ANSLY vs ABBV ($10,000, DRIP)

YearANSLY PortfolioANSLY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,961$261.40$11,550$430.00$589.00ABBV
2$11,982$253.59$13,472$627.96$1.5KABBV
3$13,066$245.35$15,906$926.08$2.8KABBV
4$14,218$236.79$19,071$1,382.55$4.9KABBV
5$15,441$228.04$23,302$2,095.81$7.9KABBV
6$16,741$219.19$29,150$3,237.93$12.4KABBV
7$18,123$210.32$37,536$5,121.41$19.4KABBV
8$19,594$201.52$50,079$8,338.38$30.5KABBV
9$21,158$192.82$69,753$14,065.80$48.6KABBV
10$22,823$184.28$102,337$24,771.77$79.5KABBV

ANSLY vs ABBV: Complete Analysis 2026

ANSLYStock

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by hospitals, surgical centers, dental practices, veterinary clinics, first responders, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia. P. D. Holdings Pty. Ltd. operates as a current subsidiary of Ansell Limited.

Full ANSLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ANSLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANSLY vs SCHDANSLY vs JEPIANSLY vs OANSLY vs KOANSLY vs MAINANSLY vs JNJANSLY vs MRKANSLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.